Karyopharm Gets FDA Fast Track Designation for Myelofibrosis Treatment
17 Julho 2023 - 5:48PM
Dow Jones News
By Ben Glickman
Karyopharm Therapeutics said Monday it received Fast Track
Designation from the U.S. Food and Drug Administration for its
treatment for myelofibrosis.
The Newton, Mass.-based pharmaceutical company said selinexor is
currently being tested in conjunction with ruxolitinib to treat a
form of myelofibrosis, a rare form of blood cancer, in a Phase 3
study. The study was initiated last month.
Fast track status from the FDA is meant to speed up the
development and review of treatments for serious and
life-threatening conditions.
Top-line data from the Phase 3 study is expected in 2025.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
July 17, 2023 16:33 ET (20:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Karyopharm Therapeutics (NASDAQ:KPTI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
